SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma
Abstract Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral corticosteroids (OCS), often at high doses, which are associated with con...
Main Authors: | Michael E. Wechsler, Gene Colice, Janet M. Griffiths, Gun Almqvist, Tor Skärby, Teresa Piechowiak, Primal Kaur, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-020-01503-z |
Similar Items
-
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
by: Corrado Pelaia, et al.
Published: (2021-04-01) -
Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children
by: Vasbinder EC, et al.
Published: (2016-04-01) -
Oral corticosteroids for asthma exacerbations might be associated with adrenal suppression: Are physicians aware of that?
by: Cristina B. Barra, et al. -
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
by: Andrew Menzies-Gow, et al.
Published: (2020-10-01) -
Factors affecting the timing of systemic corticosteroid administration in acute asthma exacerbations in an urban pediatric emergency department
by: Johnson, Laurie
Published: (2013)